In a report released on November 7, Gregory Renza from RBC Capital maintained a Hold rating on MannKind (MNKD – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $3.65.
Renza covers the Healthcare sector, focusing on stocks such as IDEAYA Biosciences, Seagen, and Alpine Immune Sciences. According to TipRanks, Renza has an average return of -0.7% and a 36.36% success rate on recommended stocks.
Currently, the analyst consensus on MannKind is a Moderate Buy with an average price target of $7.50.
See the top stocks recommended by analysts >>
Based on MannKind’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $48.61 million and a GAAP net loss of $5.27 million. In comparison, last year the company earned a revenue of $18.89 million and had a GAAP net loss of $29.02 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MannKind (MNKD) Company Description:
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
Read More on MNKD:
- MannKind reports Q3 EPS 1c, consensus (2c)
- MannKind options imply 9.3% move in share price post-earnings
- MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
- MannKind completes enrollment in Phase 4 trial in diabetes
- MNKD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
